Galactosyltransferase isoenzyme II in the detection of pancreatic cancer

Comparison with radiologic, endoscopic, and serologic tests

D. K. Podolsky, M. S. McPhee, E. Alpert, A. L. Warshaw, K. J. Isselbacher

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

We assessed the value of several serologic markers in detecting pancreatic carcinoma in a prospective study of 270 patients. The sensitivity and specificity of galactosyltransferase isoenzyme II (GT-II), carcinoembryonic antigen (CEA), alpha-fetoprotein, ferritin, C1q binding, and ribonuclease were determined. GT-II was the most sensitive (67.2 per cent) and specific (98.2 per cent) for discriminating between benign and malignant disease and was more sensitive and specific than CEA, the next most useful marker. Sensitivity was 64 per cent for ultrasound, 79.4 per cent for computerized body tomography (CBT), and 92.8 per cent for endoscopic retrograde cholangiopancreatography (ERCP). As a single test, only ERCP was more sensitive than GT-II, but more sensitive diagnoses resulted when GT-II was combined with ultrasound (92 per cent), CBT (88 per cent), or ERCP (100 per cent). Serum GT-II may be useful both by itself and in combination with imaging techniques in distinguishing benign from malignant pancreatic disease; however, this test does not dicriminate between pancreatic carcinoma and other gastrointestinal neoplasms.

Original languageEnglish (US)
Pages (from-to)1313-1318
Number of pages6
JournalNew England Journal of Medicine
Volume304
Issue number22
StatePublished - 1981

Fingerprint

Serologic Tests
Pancreatic Neoplasms
Isoenzymes
Endoscopic Retrograde Cholangiopancreatography
Carcinoembryonic Antigen
Tomography
Pancreatic Diseases
Gastrointestinal Neoplasms
alpha-Fetoproteins
Ferritins
Ribonucleases
galactosylxylosylprotein 3-beta-galactosyltransferase
Prospective Studies
Sensitivity and Specificity
Serum
Pancreatic Carcinoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Galactosyltransferase isoenzyme II in the detection of pancreatic cancer : Comparison with radiologic, endoscopic, and serologic tests. / Podolsky, D. K.; McPhee, M. S.; Alpert, E.; Warshaw, A. L.; Isselbacher, K. J.

In: New England Journal of Medicine, Vol. 304, No. 22, 1981, p. 1313-1318.

Research output: Contribution to journalArticle

@article{2a1873049512482a80618d35b875cc82,
title = "Galactosyltransferase isoenzyme II in the detection of pancreatic cancer: Comparison with radiologic, endoscopic, and serologic tests",
abstract = "We assessed the value of several serologic markers in detecting pancreatic carcinoma in a prospective study of 270 patients. The sensitivity and specificity of galactosyltransferase isoenzyme II (GT-II), carcinoembryonic antigen (CEA), alpha-fetoprotein, ferritin, C1q binding, and ribonuclease were determined. GT-II was the most sensitive (67.2 per cent) and specific (98.2 per cent) for discriminating between benign and malignant disease and was more sensitive and specific than CEA, the next most useful marker. Sensitivity was 64 per cent for ultrasound, 79.4 per cent for computerized body tomography (CBT), and 92.8 per cent for endoscopic retrograde cholangiopancreatography (ERCP). As a single test, only ERCP was more sensitive than GT-II, but more sensitive diagnoses resulted when GT-II was combined with ultrasound (92 per cent), CBT (88 per cent), or ERCP (100 per cent). Serum GT-II may be useful both by itself and in combination with imaging techniques in distinguishing benign from malignant pancreatic disease; however, this test does not dicriminate between pancreatic carcinoma and other gastrointestinal neoplasms.",
author = "Podolsky, {D. K.} and McPhee, {M. S.} and E. Alpert and Warshaw, {A. L.} and Isselbacher, {K. J.}",
year = "1981",
language = "English (US)",
volume = "304",
pages = "1313--1318",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "22",

}

TY - JOUR

T1 - Galactosyltransferase isoenzyme II in the detection of pancreatic cancer

T2 - Comparison with radiologic, endoscopic, and serologic tests

AU - Podolsky, D. K.

AU - McPhee, M. S.

AU - Alpert, E.

AU - Warshaw, A. L.

AU - Isselbacher, K. J.

PY - 1981

Y1 - 1981

N2 - We assessed the value of several serologic markers in detecting pancreatic carcinoma in a prospective study of 270 patients. The sensitivity and specificity of galactosyltransferase isoenzyme II (GT-II), carcinoembryonic antigen (CEA), alpha-fetoprotein, ferritin, C1q binding, and ribonuclease were determined. GT-II was the most sensitive (67.2 per cent) and specific (98.2 per cent) for discriminating between benign and malignant disease and was more sensitive and specific than CEA, the next most useful marker. Sensitivity was 64 per cent for ultrasound, 79.4 per cent for computerized body tomography (CBT), and 92.8 per cent for endoscopic retrograde cholangiopancreatography (ERCP). As a single test, only ERCP was more sensitive than GT-II, but more sensitive diagnoses resulted when GT-II was combined with ultrasound (92 per cent), CBT (88 per cent), or ERCP (100 per cent). Serum GT-II may be useful both by itself and in combination with imaging techniques in distinguishing benign from malignant pancreatic disease; however, this test does not dicriminate between pancreatic carcinoma and other gastrointestinal neoplasms.

AB - We assessed the value of several serologic markers in detecting pancreatic carcinoma in a prospective study of 270 patients. The sensitivity and specificity of galactosyltransferase isoenzyme II (GT-II), carcinoembryonic antigen (CEA), alpha-fetoprotein, ferritin, C1q binding, and ribonuclease were determined. GT-II was the most sensitive (67.2 per cent) and specific (98.2 per cent) for discriminating between benign and malignant disease and was more sensitive and specific than CEA, the next most useful marker. Sensitivity was 64 per cent for ultrasound, 79.4 per cent for computerized body tomography (CBT), and 92.8 per cent for endoscopic retrograde cholangiopancreatography (ERCP). As a single test, only ERCP was more sensitive than GT-II, but more sensitive diagnoses resulted when GT-II was combined with ultrasound (92 per cent), CBT (88 per cent), or ERCP (100 per cent). Serum GT-II may be useful both by itself and in combination with imaging techniques in distinguishing benign from malignant pancreatic disease; however, this test does not dicriminate between pancreatic carcinoma and other gastrointestinal neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=0019412010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019412010&partnerID=8YFLogxK

M3 - Article

VL - 304

SP - 1313

EP - 1318

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 22

ER -